SP110 and tuberculosis: In this study, we therefore tested the efficacy of ISRIB as an adjunctive therapeutic in combination with the standard TB treatment regimen (RHZ) in C3HeB/FeJ mice, which lack the SP110/Ipr1 regulator and develop human-like necrotic lung lesions following M. tuberculosis infection and are therefore particularly appropriate for evaluating the efficacy of host-directed drugs aimed at de-escalating TB-induced aberrant stress responses.